Enoxaparin sodium is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention (PCI). It binds to and potentiates the action of antithrombin, and inhibits coagulation factors XIa, IXa, Xa and IIa (thrombin), thereby preventing formation of blood clots.
Molecular Weight:
1322
CAS Number:
[679809-58-6]
Formula:
C42H59N3Na4O35S2
Target:
Factor Xa|||Thrombin|||SARS-CoV
* VAT and and shipping costs not included. Errors and price changes excepted